Solentim to launch the ICON™ in 2021
Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021.
For over a decade, Solentim has provided leading solutions to create, isolate and characterize the highest value cells, accelerating the development of new biological medicines and therapies around the world, in cell line development, vaccine research, stem cell biotherapeutics and gene therapy.
In 2021, a new platform will be launched. Empowering laboratories to make better decisions faster.
View the trailer and sign up for our exclusive ICON newsletter.